[{"from": "human", "value": "Provide a description of this molecule. [C][=C][C][=C][Branch2][Ring1][#C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=N][C][=Branch1][Branch1][=N][O][Ring1][Branch1][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][O][F]"}, {"from": "gpt", "value": "The molecule is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a \u2018nonsense mutation\u2019) in the dystrophin gene.  This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications."}]